MRNA Moderna, Inc.
What matters nowUpdated 6 h ago
- On September 30, 2026 Moderna created a chief operating officer role and appointed Juan Andres, effective October 5, 2026; Jerh Collins, Chief Technical Operations and Quality Officer, will retire, and the company tied the change to preparing for a possible launch of intismeran autogene 1.
- Citi downgraded Moderna to Sell from Neutral on September 30 and raised its price target from $60 to $80, arguing the valuation had run ahead of expected revenue and earnings; the shares fell about 6% to around $191 in early trading that day 2.
- MRNA traded at $214.86 on the pooled 24/7 venue price, up 0.90% from the previous close of $212.95. It rose 15.11% on October 9, the day Moderna's return to the Nasdaq-100 took effect, replacing Warner Bros. Discovery 3, and fell 5.17% on October 12.
- Trailing revenue is $2.23 billion, down 27.6% year on year as of June 30, 2026, with a trailing net loss of $3.15 billion, free cash flow of -$1.24 billion and a 23.4% gross margin; the market value is $85.7 billion, or 38.5 times trailing sales, and the company holds net cash of $1.13 billion. Insiders sold $55.4 million of stock over the last 180 days across 11 sales, 10 of them under pre-arranged trading plans, and made no purchases; President Stephen Hoge's September sales of about 80,600 shares under such a plan were worth about $11.7 million 4.
- Q3 2026 results are estimated for November 5, 2026 and are not yet confirmed; the pivotal readout for the propionic acidemia therapy mRNA-3927 is expected by the end of 2026, and Q4 and full-year results are estimated for February 2027.
- Polymarket odds for the October 2026 Fed meeting are 81.5% for no change in rates and 17.5% for a 25 basis point increase, with September CPI due on October 14.
SEC (Moderna Form 8-K) · Sep 30
24/7 Wall St. · Sep 30
Nasdaq · Oct 1
SEC Form 4 · Sep 14
Valuation & fundamentalsFull financials →
TTM through 2026-06-30 from SEC filings (some quarters derived from annual and year-to-date figures). Ratios use our pooled 24/7 price. Quarterly statements →
Every venue
| Venue | Price | vs pool | 24h vol | Open int. | Funding 8h |
|---|---|---|---|---|---|
| binance perp MRNAUSDT · just now | 215.41 | +0.01% | $14.0M | $2.3M | 0.0381% |
| hyperliquid perp xyz:MRNA · just now | 215.21 | −0.09% | $8.1M | $3.1M | 0.0050% |
| okx perp MRNA-USDT-SWAP · just now | 215.27 | −0.06% | $4.5M | $1.9M | 0.0000% |
| bitget perp MRNAUSDT · just now | 215.43 | +0.02% | $3.3M | $1.1M | 0.0000% |
| lighter perp 228 · just now | 215.39 | 0.00% | $1.8M | $146.4K | 0.0424% |
| bybit perp MRNAUSDT · just now | 215.38 | 0.00% | $1.2M | $758.7K | 0.0000% |
| aster perp MRNAUSDT · just now | 216.10 | +0.33% | $144.0K | $45.1K | 0.0000% |
Pooled price = volume-weighted median of venues within 2% of each other. Venue markets for stocks, indices and gold are 24/7 perpetual contracts; they track but are not the official exchange price.
Open interest, 120 days
US$ millions, all venues
Funding, 120 days
Annualised %, OI-weighted. Positive: longs pay shorts.
NewsAll news →
Moderna to join the Nasdaq-100 index, replacing Warner Bros. Discovery
Nasdaq said Moderna will become a component of the Nasdaq-100 Index before the market opened on October 9, 2026, replacing Warner Bros.
Citi downgrades Moderna to Sell and raises price target to $80
Citi analyst Geoff Meacham cut Moderna from Neutral to Sell and lifted the price target from $60 to $80.
Moderna names Juan Andres chief operating officer; Jerh Collins to retire
Moderna created a new chief operating officer role and appointed Juan Andres, a former Moderna technical operations executive who left in 2023, to fill it, effective October 5, 2026.
Moderna President Stephen Hoge sells about 80,600 shares under a trading plan
Moderna President Stephen Hoge sold 80,575 shares on September 14 and 15, 2026, at weighted average prices of about $144 and $146, for roughly $11.7 million in total.
CFO James Mock sells 34,836 shares at $134.49 under a trading plan
Chief Financial Officer James Mock exercised 19,836 options at $30.96 and sold 34,836 shares at $134.49 on September 10, 2026, for about $4.7 million.
Chief Legal Officer Shannon Thyme Klinger sells 3,471 shares
Chief Legal Officer Shannon Thyme Klinger sold 3,471 shares at $139.95 on September 1, 2026, about $0.5 million, after exercising options at $30.96.
Moderna to present at Morgan Stanley and Bernstein healthcare conferences in September
Moderna said it will present at two investor conferences in September 2026: the Morgan Stanley 24th Annual Global Healthcare Conference on September 14 and the Bernstein healthcare forum on September 23.
FDA approves updated 2026-2027 Spikevax and mNEXSPIKE COVID-19 vaccines
The FDA approved Moderna's updated 2026-2027 COVID-19 vaccines, Spikevax and mNEXSPIKE, which both target the JN.1-lineage XFG subvariant.
Intismeran autogene with KEYTRUDA beats Keytruda alone in Phase 3 melanoma trial
Merck and Moderna said the Phase 3 INTerpath-001 trial met its primary endpoint of recurrence-free survival and its key secondary endpoint of distant metastasis-free survival, with the combination improving both over KEYTRUDA alone in patients with completely resected melanoma.
FDA approves Moderna's mFLUSIVA, the first US mRNA flu vaccine, for adults 50 and older
The FDA approved mFLUSIVA (mRNA-1010), Moderna's seasonal flu vaccine, for adults 50 and older.
Moderna Q2 2026 revenue rises to $145 million; 2026 guidance kept, R&D outlook cut
Moderna reported Q2 2026 total revenue of $145 million, up from $142 million a year earlier, while net product sales fell to $94 million from $114 million.
Former Biogen CFO Michael McDonnell joins Moderna board and Audit Committee
Moderna appointed Michael McDonnell to its board of directors effective July 8, 2026, as a Class II director with a term to the 2029 annual meeting, and to the Audit Committee.
FDA advisory committee votes 9-0 for Moderna's mRNA flu vaccine in both age groups
The FDA's vaccine advisory committee voted 9-0 that the benefits of mRNA-1010 outweigh its risks for adults 50 to 64, and also voted 9-0 for adults 65 and older.
Moderna hires Ester Banque as Chief Commercial Officer and widens Stephen Hoge's remit
Moderna named Ester Banque Chief Commercial Officer, effective June 15, 2026, with a seat on the Executive Committee reporting to CEO Stephane Bancel.
Five-year Phase 2b melanoma data: intismeran plus KEYTRUDA cuts recurrence risk 49%
Moderna and Merck presented five-year Phase 2b data for intismeran autogene plus KEYTRUDA at ASCO, showing a 49% lower risk of recurrence or death than KEYTRUDA alone in 157 patients with high-risk melanoma.